Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Daiichi Sankyo
Colorcon
Argus Health
Cantor Fitzgerald
UBS
US Department of Justice
Deloitte
Mallinckrodt
Express Scripts

Generated: January 19, 2018

DrugPatentWatch Database Preview

CANCIDAS Drug Profile

« Back to Dashboard

When do Cancidas patents expire, and when can generic versions of Cancidas launch?

Cancidas is a drug marketed by Merck and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-one patent family members in forty countries.

The generic ingredient in CANCIDAS is caspofungin acetate. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the caspofungin acetate profile page.
Summary for CANCIDAS
Drug patent expirations by year for CANCIDAS
Pharmacology for CANCIDAS
Ingredient-typeLipopeptides
Drug ClassEchinocandin Antifungal

US Patents and Regulatory Information for CANCIDAS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-001 Jan 26, 2001 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-002 Jan 26, 2001 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-001 Jan 26, 2001 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-002 Jan 26, 2001 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for CANCIDAS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-001 Jan 26, 2001 ➤ Subscribe ➤ Subscribe
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-002 Jan 26, 2001 ➤ Subscribe ➤ Subscribe
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-001 Jan 26, 2001 ➤ Subscribe ➤ Subscribe
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-002 Jan 26, 2001 ➤ Subscribe ➤ Subscribe
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-002 Jan 26, 2001 ➤ Subscribe ➤ Subscribe
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-002 Jan 26, 2001 ➤ Subscribe ➤ Subscribe
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-002 Jan 26, 2001 ➤ Subscribe ➤ Subscribe
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-001 Jan 26, 2001 ➤ Subscribe ➤ Subscribe
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-001 Jan 26, 2001 ➤ Subscribe ➤ Subscribe
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-001 Jan 26, 2001 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for CANCIDAS
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe For Injection 50 mg/vial and 70 mg/vial ➤ Subscribe 6/26/2009

International Patents for CANCIDAS

Supplementary Protection Certificates for CANCIDAS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/002 United Kingdom ➤ Subscribe A SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016.
00076 Netherlands ➤ Subscribe PRODUCT NAME: CASPOFUNGINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT, IN HET BIJZONDER CASPOFUNGINE ACETAAT; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024
C0054 France ➤ Subscribe PRODUCT NAME: CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001 20011024
01/029 Ireland ➤ Subscribe PRODUCT NAME: CASPOFUNGIN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024; PAEDIATRIC INV. PLAN: P/30/2008
/2001 Austria ➤ Subscribe PRODUCT NAME: CASPOFUNGIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE CASPOFUNGINACETAT; REGISTRATION NO/DATE: EU/01/196/001-003 20011024
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Cerilliant
Farmers Insurance
Moodys
US Army
UBS
Colorcon
Fuji
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot